PUBLISHER: DelveInsight | PRODUCT CODE: 1127387
PUBLISHER: DelveInsight | PRODUCT CODE: 1127387
DelveInsight's , "Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2022," report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Intrahepatic Cholangiocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy arising from the liver. ICC makes up about 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals. Histologically, the majority of ICCs are adenocarcinomas. ICC mostly develops as a well-differentiated adenocarcinoma. Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene. The most commonly used classification system to qualify advancement and resectability of ICC is the American Joint Committee on Cancer (AJCC) TNM staging system, currently in its seventh edition, consisting of four stages.
"Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Intrahepatic Cholangiocarcinoma pipeline landscape is provided which includes the disease overview and Intrahepatic Cholangiocarcinoma treatment guidelines. The assessment part of the report embraces, in depth Intrahepatic Cholangiocarcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Intrahepatic Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Intrahepatic Cholangiocarcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Derazantinib is an investigational orally administered small-molecule FGFR inhibitor with strong activity against FGFR1, 2, and 3.2 FGFR kinases are key drivers of cell proliferation, differentiation and migration. FGFR genetic aberrations, e.g. gene fusions, mutations or amplifications, have been identified as potentially important therapeutic targets for various cancers, including intrahepatic cholangiocarcinoma (iCCA), urothelial, breast, gastric and lung cancers.
This segment of the report provides insights about the different Intrahepatic Cholangiocarcinoma drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 18+ key companies which are developing the therapies for Intrahepatic Cholangiocarcinoma. The companies which have their Intrahepatic Cholangiocarcinoma drug candidates in the most advanced stage, i.e. phase II include, Basilea Pharmaceutica.
DelveInsight's report covers around 20+ products under different phases of clinical development like:
Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
Products have been categorized under various Molecule types such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Intrahepatic Cholangiocarcinoma therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Intrahepatic Cholangiocarcinoma drugs.